Addressing extreme cost and lack of catheter lock options in the U.S.

The FDA’s unapproved drug initiative has had an impact on catheter lock therapy for home infusion patients. Patients who require a central venous access device (CVAD) are at a significant risk for catheter-associated bloodstream infections. The lack of options and high cost have created an urgent need in the U.S. for FDA-approved central line catheter lock solutions.

In this white paper learn about:

• Challenges and costs of Ethanol Lock Therapy (ELT)
• Need for FDA-approved alternative lock solutions

Download white paper